DecisionDx-Melanoma Test Significantly Enhances SLN Positivity Prediction Accuracy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 25 2026
0mins
Source: Newsfilter
- Enhanced Test Accuracy: A newly published prospective study demonstrates that DecisionDx-Melanoma's i31-SLNB test identifies low and high-risk patients with a sentinel lymph node (SLN) positivity rate of 2.6%, significantly below the 5% threshold set by the National Comprehensive Cancer Network (NCCN), indicating its critical value in clinical decision-making.
- Clinical Application Potential: The i31-SLNB test outperforms the traditional MIA nomogram in assessing SLN positivity risk, which reported a positivity rate of 5.8%, suggesting that i31-SLNB can more effectively assist clinicians in determining which patients may safely avoid SLNB surgery, thereby reducing unnecessary surgical risks.
- Risk Classification Consistency: The study found that the positivity rate for patients classified as low risk by the i31-SLNB was 2.8%, while the MIA model indicated a rate of 11.5% for the same group, demonstrating the consistency and accuracy of i31-SLNB in risk classification, further supporting its clinical application.
- Study Scale and Impact: Evaluating 912 patients considering SLNB, the study revealed an AUC of 0.74 for the i31-SLNB test, significantly higher than the MIA model's 0.61, emphasizing the importance of integrating tumor biology with clinicopathologic features to improve risk assessment and management for melanoma patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CSTL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CSTL
Wall Street analysts forecast CSTL stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.710
Low
41.00
Averages
47.20
High
52.00
Current: 24.710
Low
41.00
Averages
47.20
High
52.00
About CSTL
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DecisionDx-Melanoma Test Significantly Enhances Risk Assessment
- Enhanced Test Accuracy: A newly published prospective study demonstrates that DecisionDx-Melanoma's i31-SLNB test significantly outperforms the MIA nomogram in identifying low and high-risk patients, aiding clinicians in making informed decisions regarding sentinel lymph node biopsy (SLNB).
- Low-Risk Patient Outcomes: The i31-SLNB test reduces the observed sentinel lymph node positivity rate for low-risk patients to 2.6%, well below the NCCN's 5% threshold, indicating its effectiveness in identifying patients who can safely avoid unnecessary surgical risks.
- High-Risk Patient Identification: Among patients classified as low risk by the i31-SLNB but higher risk by the MIA nomogram, the observed positivity rate was only 2.8%, while the MIA model indicated 11.5%, showcasing the i31-SLNB's superiority in accurately identifying high-risk individuals.
- Significant Clinical Implications: The study underscores the importance of integrating tumor biology with clinicopathologic features, advancing personalized management for melanoma patients and enhancing survival rates and treatment outcomes.
See More
DecisionDx-Melanoma Test Significantly Enhances SLN Positivity Prediction Accuracy
- Enhanced Test Accuracy: A newly published prospective study demonstrates that DecisionDx-Melanoma's i31-SLNB test identifies low and high-risk patients with a sentinel lymph node (SLN) positivity rate of 2.6%, significantly below the 5% threshold set by the National Comprehensive Cancer Network (NCCN), indicating its critical value in clinical decision-making.
- Clinical Application Potential: The i31-SLNB test outperforms the traditional MIA nomogram in assessing SLN positivity risk, which reported a positivity rate of 5.8%, suggesting that i31-SLNB can more effectively assist clinicians in determining which patients may safely avoid SLNB surgery, thereby reducing unnecessary surgical risks.
- Risk Classification Consistency: The study found that the positivity rate for patients classified as low risk by the i31-SLNB was 2.8%, while the MIA model indicated a rate of 11.5% for the same group, demonstrating the consistency and accuracy of i31-SLNB in risk classification, further supporting its clinical application.
- Study Scale and Impact: Evaluating 912 patients considering SLNB, the study revealed an AUC of 0.74 for the i31-SLNB test, significantly higher than the MIA model's 0.61, emphasizing the importance of integrating tumor biology with clinicopathologic features to improve risk assessment and management for melanoma patients.
See More
Castle Biosciences Grants Restricted Stock Units to Employees
- Employee Incentive Program: On June 15, 2026, Castle Biosciences granted 204,925 restricted stock units (RSUs) to 172 employees as an inducement for their employment, highlighting the company's commitment to attracting talent.
- Grant Details: The RSUs were awarded under the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), vesting over four years with 25% vesting on the first anniversary and the remainder in three equal annual installments, ensuring continued employee service.
- Company Background: Castle Biosciences focuses on diagnostics for dermatologic and gastroenterological diseases, aiming to improve patient care through innovative tests that enhance disease management and patient outcomes, showcasing its leadership in the healthcare sector.
- Market Impact: By implementing such incentive measures, Castle Biosciences not only boosts employee loyalty and engagement but also enhances its attractiveness and innovative capacity in a highly competitive healthcare market.
See More
Castle Biosciences Grants Restricted Stock Units to Employees
- Employee Incentive Program: On June 15, 2026, Castle Biosciences granted 204,925 restricted stock units (RSUs) to 172 employees as an inducement for their employment, reflecting the company's commitment to attracting and retaining talent.
- Grant Details: The RSUs were awarded under the company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), vesting over four years with 25% vesting on the first anniversary and the remainder in three equal annual installments.
- Long-term Service Commitment: Employees must continue their service through each vesting date to receive the shares, which not only enhances employee retention but also fosters a long-term partnership between the company and its workforce.
- Strategic Company Development: By implementing this incentive program, Castle Biosciences aims to boost employee motivation and loyalty, thereby driving innovation and competitiveness in the dermatologic and gastroenterological sectors.
See More
Castle Biosciences Surpasses 100,000 TissueCypher Test Orders
- Order Milestone: Castle Biosciences has surpassed 100,000 clinical test orders for its TissueCypher® Barrett's Esophagus Test, indicating robust growth in the personalized medicine sector and reflecting increasing market demand for precision healthcare solutions.
- Risk Assessment Capability: The TissueCypher test predicts a patient's five-year risk of progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma, enabling clinicians to tailor management strategies based on individual risk profiles, thereby enhancing treatment outcomes for patients.
- Clinical Validation Support: The test has been studied in biopsies from over 8,000 patients and is backed by more than 17 peer-reviewed publications, demonstrating its unique advantages over traditional histopathological risk assessments and further solidifying Castle Biosciences' leadership in the diagnostics field.
- Improved Patient Experience: Patient Robin Byrd Wilfong received a low-risk result from TissueCypher, indicating only a 2% chance of progression over five years, which not only alleviated her anxiety but also empowered her to manage her health more effectively, highlighting the test's significance in providing psychological support to patients.
See More
Castle Biosciences to Present at 2026 Jefferies Global Healthcare Conference
- Conference Presentation: Castle Biosciences is scheduled to present a company overview at the 2026 Jefferies Global Healthcare Conference on June 3 at 1:20 p.m. Eastern time, showcasing its innovative testing solutions aimed at improving health and attracting investor interest.
- Live Webcast Availability: The presentation will be available via live audio webcast on Castle Biosciences' website, allowing real-time access for attendees, with a replay option provided post-event to ensure that key information reaches all interested investors.
- Company Background: Castle Biosciences focuses on diagnostics for dermatologic and gastroenterological diseases, developing personalized, clinically actionable solutions that enhance disease management and patient outcomes, highlighting its innovative capabilities and market potential in the healthcare sector.
- Brand and Products: The company boasts a range of trademarks and products, including the DecisionDx series, underscoring its leadership in molecular testing and personalized medicine, which further solidifies its market share and influence in the diagnostics industry.
See More
DecisionDx-Melanoma Test Significantly Enhances Risk Assessment
- Enhanced Test Accuracy: A newly published prospective study demonstrates that DecisionDx-Melanoma's i31-SLNB test significantly outperforms the MIA nomogram in identifying low and high-risk patients, aiding clinicians in making informed decisions regarding sentinel lymph node biopsy (SLNB).
- Low-Risk Patient Outcomes: The i31-SLNB test reduces the observed sentinel lymph node positivity rate for low-risk patients to 2.6%, well below the NCCN's 5% threshold, indicating its effectiveness in identifying patients who can safely avoid unnecessary surgical risks.
- High-Risk Patient Identification: Among patients classified as low risk by the i31-SLNB but higher risk by the MIA nomogram, the observed positivity rate was only 2.8%, while the MIA model indicated 11.5%, showcasing the i31-SLNB's superiority in accurately identifying high-risk individuals.
- Significant Clinical Implications: The study underscores the importance of integrating tumor biology with clinicopathologic features, advancing personalized management for melanoma patients and enhancing survival rates and treatment outcomes.
See More
DecisionDx-Melanoma Test Significantly Enhances SLN Positivity Prediction Accuracy
- Enhanced Test Accuracy: A newly published prospective study demonstrates that DecisionDx-Melanoma's i31-SLNB test identifies low and high-risk patients with a sentinel lymph node (SLN) positivity rate of 2.6%, significantly below the 5% threshold set by the National Comprehensive Cancer Network (NCCN), indicating its critical value in clinical decision-making.
- Clinical Application Potential: The i31-SLNB test outperforms the traditional MIA nomogram in assessing SLN positivity risk, which reported a positivity rate of 5.8%, suggesting that i31-SLNB can more effectively assist clinicians in determining which patients may safely avoid SLNB surgery, thereby reducing unnecessary surgical risks.
- Risk Classification Consistency: The study found that the positivity rate for patients classified as low risk by the i31-SLNB was 2.8%, while the MIA model indicated a rate of 11.5% for the same group, demonstrating the consistency and accuracy of i31-SLNB in risk classification, further supporting its clinical application.
- Study Scale and Impact: Evaluating 912 patients considering SLNB, the study revealed an AUC of 0.74 for the i31-SLNB test, significantly higher than the MIA model's 0.61, emphasizing the importance of integrating tumor biology with clinicopathologic features to improve risk assessment and management for melanoma patients.
See More
Castle Biosciences Grants Restricted Stock Units to Employees
- Employee Incentive Program: On June 15, 2026, Castle Biosciences granted 204,925 restricted stock units (RSUs) to 172 employees as an inducement for their employment, highlighting the company's commitment to attracting talent.
- Grant Details: The RSUs were awarded under the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), vesting over four years with 25% vesting on the first anniversary and the remainder in three equal annual installments, ensuring continued employee service.
- Company Background: Castle Biosciences focuses on diagnostics for dermatologic and gastroenterological diseases, aiming to improve patient care through innovative tests that enhance disease management and patient outcomes, showcasing its leadership in the healthcare sector.
- Market Impact: By implementing such incentive measures, Castle Biosciences not only boosts employee loyalty and engagement but also enhances its attractiveness and innovative capacity in a highly competitive healthcare market.
See More
Castle Biosciences Grants Restricted Stock Units to Employees
- Employee Incentive Program: On June 15, 2026, Castle Biosciences granted 204,925 restricted stock units (RSUs) to 172 employees as an inducement for their employment, reflecting the company's commitment to attracting and retaining talent.
- Grant Details: The RSUs were awarded under the company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), vesting over four years with 25% vesting on the first anniversary and the remainder in three equal annual installments.
- Long-term Service Commitment: Employees must continue their service through each vesting date to receive the shares, which not only enhances employee retention but also fosters a long-term partnership between the company and its workforce.
- Strategic Company Development: By implementing this incentive program, Castle Biosciences aims to boost employee motivation and loyalty, thereby driving innovation and competitiveness in the dermatologic and gastroenterological sectors.
See More
Castle Biosciences Surpasses 100,000 TissueCypher Test Orders
- Order Milestone: Castle Biosciences has surpassed 100,000 clinical test orders for its TissueCypher® Barrett's Esophagus Test, indicating robust growth in the personalized medicine sector and reflecting increasing market demand for precision healthcare solutions.
- Risk Assessment Capability: The TissueCypher test predicts a patient's five-year risk of progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma, enabling clinicians to tailor management strategies based on individual risk profiles, thereby enhancing treatment outcomes for patients.
- Clinical Validation Support: The test has been studied in biopsies from over 8,000 patients and is backed by more than 17 peer-reviewed publications, demonstrating its unique advantages over traditional histopathological risk assessments and further solidifying Castle Biosciences' leadership in the diagnostics field.
- Improved Patient Experience: Patient Robin Byrd Wilfong received a low-risk result from TissueCypher, indicating only a 2% chance of progression over five years, which not only alleviated her anxiety but also empowered her to manage her health more effectively, highlighting the test's significance in providing psychological support to patients.
See More
Castle Biosciences to Present at 2026 Jefferies Global Healthcare Conference
- Conference Presentation: Castle Biosciences is scheduled to present a company overview at the 2026 Jefferies Global Healthcare Conference on June 3 at 1:20 p.m. Eastern time, showcasing its innovative testing solutions aimed at improving health and attracting investor interest.
- Live Webcast Availability: The presentation will be available via live audio webcast on Castle Biosciences' website, allowing real-time access for attendees, with a replay option provided post-event to ensure that key information reaches all interested investors.
- Company Background: Castle Biosciences focuses on diagnostics for dermatologic and gastroenterological diseases, developing personalized, clinically actionable solutions that enhance disease management and patient outcomes, highlighting its innovative capabilities and market potential in the healthcare sector.
- Brand and Products: The company boasts a range of trademarks and products, including the DecisionDx series, underscoring its leadership in molecular testing and personalized medicine, which further solidifies its market share and influence in the diagnostics industry.
See More
